Yihang Fu

Ms. Yihang Fu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YFYihang Fu
Yihang Fu
WXWei Xiao
Wei Xiao
YMYu-Xiang Mao
Yu-Xiang Mao
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Compared to cutaneous melanoma (CM), which mainly harbors BRAF or NRAS mutations, UM predominantly harbors GNAQ or GNA11 mutations. Although primary UM can be controlled locally, approximately 50% of patients still develop metastases. To date, there have been no standard therapeutic strategies for the prevention or treatment of metastases. Unfortunately, chemotherapy and targeted therapies only induce minimal responses in patients with metastatic UM, with a median survival time of only 4–5 months after metastasis detection. Immunotherapy agents, such as immune checkpoint inhibitors, have achieved pioneering outcomes in CM but have shown limited effects in UM. Researchers have explored several feasible checkpoints to identify options for future therapies. Cancer vaccines have shown little in the way of therapeutic benefit in patients with UM, and there are few ongoing trials providing favorable evidence, but adoptive cell transfer-related therapies seem promising and deserve further investigation. More recently, the immune-mobilizing monoclonal T-cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors have also gained ground. This review highlights recent progress in burgeoning treatments and provides innovative insights on feasible strategies for the treatment of UM.

28 February 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
YFYihang Fu
Yihang Fu
XCXiaoyun Chen
Xiaoyun Chen
SLSheng Luo
Sheng Luo
SJShuangyan Jiang
Shuangyan Jiang
YMYu-Xiang Mao
Yu-Xiang Mao
WXWei Xiao
Wei Xiao
Background: Age-related macular degeneration (AMD) has been the leading cause of irreversible blindness in industrialized countries. Emerging data suggest that serum vitamin D levels may be associated with AMD but show mixed results. National-level population data on the relationship between vitamin D and AMD severities are still lacking. Methods: We used data from the National Health and Nutrition Examination Survey (NHANES) 2005 to 2008. Retinal photographs were taken and graded for AMD stage. The odds ratio (OR) of AMD and its subtype was calculated after adjusting for confounding factors. Restricted cubic spline (RCS) analyses were used to explore potential non-linear relations. Results: A total of 5041 participants with a mean age of 59.6 years were included. After adjusting for covariates, participants with higher level of serum 25-hydroxyvitamin D [25(OH)D] had significantly greater odds of early AMD (OR, 1.65; 95% CI, 1.08–2.51) and decreased risk of late AMD (OR, 0.29; 95% CI, 0.09–0.88). When stratified by age, a positive association between the level of serum 25(OH)D and early AMD was present in the <60 years group (OR, 2.79; 95% CI, 1.08–7.29), whereas a negative relation between the level of serum 25(OH)D and late AMD was detected in the ≥60 years group (OR, 0.24; 95% CI, 0.08–0.76). Conclusions: A higher level of serum 25(OH)D was related to increased risk of early AMD in those <60 years and decreased risk of late AMD in those ≥60 years.

7 August 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
YFYihang Fu
Yihang Fu
MAMathilde Amiot
Mathilde Amiot
IKIsabelle Kuzniak
Isabelle Kuzniak
FJFanélie Jouenne
Fanélie Jouenne
Samia MourahSamia Mourah
Samia Mourah
Nicolas DumazNicolas Dumaz
Nicolas Dumaz